Pregnancy outcomes of managed medicaid members prescribed home administration of 17 α-hydroxyprogesterone caproate

American Journal of Perinatology

Volumn 29, Issue 7, 2012, Pages 489-495

  Lucas, Brad ^a   Poole Yaeger, Amy ^a   Istwan, Niki ^b   Stanziano, Gary ^b   Rhea, Debbie ^b   Mason, Mary ^a  

^a CENTENE CORPORATION   (United States)

^b Department of Clinical Research ^*  (United States)

Author keywords

17 alpha hydroxyprogesterone caproate (17P); case management; managed care; Medicaid; recurrent spontaneous preterm birth

Indexed keywords

HYDROXYPROGESTERONE CAPROATE;

ADULT; ARTICLE; CERCLAGE; CONTROLLED STUDY; FEMALE; GESTATIONAL AGE; HEALTH CARE PLANNING; HEALTH SERVICE; HUMAN; MEDICAID; MEDICAL EDUCATION; NURSE; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PERINATAL CARE; PHYSICIAN; PRACTICE GUIDELINE; PREGNANCY OUTCOME; PREMATURE LABOR; PRESCRIPTION; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; SPONTANEOUS ABORTION; STILLBIRTH; TELEPHONE;

ADOLESCENT; ADULT; FEMALE; GESTATIONAL AGE; GUIDELINE ADHERENCE; HOME CARE SERVICES; HUMANS; HYDROXYPROGESTERONES; INFANT, NEWBORN; INFANT, PREMATURE; MEDICAID; MEDICATION ADHERENCE; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREGNANCY OUTCOME; PREMATURE BIRTH; PROGESTINS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84864137569     PISSN: 07351631     EISSN: 10988785     Source Type: Journal    
DOI: 10.1055/s-0032-1304833     Document Type: Article

References (14)

1. American Academy of Pediatrics. Fact Sheet: Medicaid and Children. July 10, 2011. Available at: http://www.aap.org/research/factsheet.pdf. Accessed August 23, 2011
2. Kaiser Family Foundation. Available at: http://www.statehealthfacts.org. Accessed August 23, 2011
3. Kaiser Family Foundation. Policy Brief. Medicaid and managed care: key data, trends and issues. February 2010. Available at: http://www.kff.org/ medicaid/upload/8046.pdf. Accessed August 23, 2011
4. Mercer BM, Goldenberg RL, Moawad AH., et al. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. The preterm prediction study: effect of gestational age and cause of preterm birth on subsequent obstetric outcome. Am J Obstet Gynecol: 1999; 181 5 Pt 1 1216 1221
5. Meis PJ, Klebanoff M, Thom E., et al. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med: 2003; 348 2379 2385 (Pubitemid 36682816)
6. Rittenberg C, Sullivan S, Istwan N, Rhea D, Stanziano G, Newman R. Clinical characteristics of women prescribed 17 alpha-hydroxyprogesterone caproate in the community setting. Am J Obstet Gynecol: 2007; 197 262, e1 e4
7. Mason MV, Poole-Yaeger A, Krueger CR, House KM, Lucas B. Impact of 17P usage on NICU admissions in a managed Medicaid populationa five-year review. Manag Care: 2010; 19 46 52
8. Mason MV, Poole-Yaeger A, Lucas B, Krueger CR, Ahmed T, Duncan I. Effects of a pregnancy management program on birth outcomes in managed Medicaid. Manag Care: 2011; 20 39 46
9. Rebarber A, Fox NS, Klauser CK., et al. Using 17 α- hydroxyprogesterone caproate to impact rates of recurrent preterm delivery in clinical practice. J Matern Fetal Neonatal Med: 2010; 23 1139 1142
10. González-Quintero VH, Istwan NB, Rhea DJ, Smarkusky L, Hoffman MC, Stanziano GJ. Gestational age at initiation of 17-hydroxyprogesterone caproate (17P) and recurrent preterm delivery. J Matern Fetal Neonatal Med: 2007; 20 249 252 (Pubitemid 47221617)
11. How HY, Barton JR, Istwan NB, Rhea DJ, Stanziano GJ. Prophylaxis with 17 alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery: does gestational age at initiation of treatment matter? Am J Obstet Gynecol: 2007; 197 260, e1 e4
12. Mason MV, House KM, Linehan J, Speers CA, Joseph LM, Littlejohn R. Optimizing the use of 17P in pregnant managed Medicaid members. Manag Care: 2008; 17 47 52
13. Rebarber A, Ferrara LA, Hanley ML., et al. Increased recurrence of preterm delivery with early cessation of 17-alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol: 2007; 196 224, e1 e4
14. Mason MV, House KM, Fuest CM, Fitzgerald DR, Kitson BJ, Inglis JA. 17 alpha-hydroxyprogesterone caproate (17P) usage in a Medicaid managed care plan and reduction in neonatal intensive care unit days. Manag Care: 2005; 14 58 63